MedPath

Curosurf/Budesonide for Infants With Respiratory Distress Syndrome

Not Applicable
Completed
Conditions
Respiratory Distress Syndrome
Interventions
Registration Number
NCT02013115
Lead Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Brief Summary

Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome usually need the second or more pulmonary surfactant and is easier to developing to Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome, Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of Brochopulmonary dysplasia.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Clinical diagnosis of respiratory distress syndrome
Exclusion Criteria
  • pneumothorax
  • surgical disease
  • major congenical defects

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cursurf and BudesonideBudesonideThe baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.
Primary Outcome Measures
NameTimeMethod
need of pulmonary surfactantone month

The hypothesis is Cursurf/Budesonide could reduced the need of pulmonary surfactant

Secondary Outcome Measures
NameTimeMethod
the incidence of bronchopulmonary dysplasiagestional age 36 weeks or later

the hypothesis is Cursurf and Budesonide could reduced the incidence of bronchopulmonary dysplasia.

Trial Locations

Locations (1)

Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University

🇨🇳

Chongqing, Chongqing, China

© Copyright 2025. All Rights Reserved by MedPath